Creative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs is offering the most comprehensive services for antibody development projects. With strict regulation and effective execution, we are dedicated to providing the most valuable solutions to complete your projects.
HighlightsCreative Biolabs has established a broad range of platforms for developing novel antibodies or equivalents. These cutting-edge technologies enable our scientists to meet your demands from different aspects and tailor the most appropriate solution that contributes to the success of your projects.
HighlightsWith deep understanding in antibody-related realms and extensive project experience, Creative Biolabs offers a variety of references to help you learn more about our capacities and achievements, including infographic, flyer, case study, peer-reviewed publications, and all kinds of knowledge that can assist your projects. You are also welcome to contact us directly for more specific solutions.
HighlightsGet a real taste of Creative Biolabs, one of the most professional custom service providers in the world. We are committed to providing highly customized comprehensive solutions with the best quality to advance your projects.
HighlightsIn the vanguard of modern therapeutics, human monoclonal antibodies (hMAbs) represent the most successful and rapidly expanding class of biopharmaceuticals. Their exquisite specificity, high affinity, and intrinsic human origin minimize immunogenicity, making them powerful tools for treating a spectrum of diseases, from oncology to infectious and autoimmune disorders. Creative Biolabs stands at the forefront of this revolution. With over two decades of dedicated expertise, we have engineered a world-class platform for Human Monoclonal Antibody Discovery. We harness the profound power of the human immune system, translating its optimized responses into therapeutic-grade antibodies. Our flagship service centers on the industry's most robust technology: phage display-based Human Monoclonal Antibody Discovery, utilizing proprietary, high-diversity human immunized antibody libraries.
The discovery of a successful therapeutic antibody is a formidable challenge. The ideal candidate must possess a suite of characteristics:
Traditional methods, such as murine hybridoma followed by humanization, are time-consuming and often result in antibodies with suboptimal properties or residual immunogenic epitopes. While transgenic mice expressing human Ig loci are effective, they represent a significant investment in time and resources. Creative Biolabs bypasses these limitations by going directly to the source: the in vivo matured human B-cell repertoire.
Phage display is a Nobel Prize-winning technology that has revolutionized antibody discovery. It provides a direct and powerful link between the antibody's genetic code (genotype) and its functional protein (phenotype), enabling the screening of vast libraries—billions or even trillions of unique antibody candidates—in a single test tube.
At Creative Biolabs, we have refined phage display into a precision-engineered discovery engine. Our platform is not merely about library size; it is about library quality. We specialize in the construction and screening of human immune antibody libraries, a strategy that leverages nature's own affinity maturation process to deliver antibodies of unparalleled quality.
While naïve and synthetic libraries offer diversity, they are fundamentally "uneducated." They represent a starting point.
An immune antibody library, by contrast, is a curated collection of antibodies from donors who have mounted a successful immune response to a specific antigen (e.g., a pathogen, vaccine, or tumor). The B-cells in these donors have already undergone in vivo somatic hypermutation and affinity selection within germinal centers.
This means the antibodies we isolate are:
This immune antibody library for Human Monoclonal Antibody Discovery is the cornerstone of our platform, providing a faster and more reliable path to clinically relevant candidates.
Fig. 1 Selection of anti-OX40 scFv antibodies.1
Our approach combines the high-throughput power of phage display with the biological superiority of the human immune response.
| Feature | Advantage | Scientific Rationale |
| Human Immune Source | Superior Affinity & Specificity | Antibodies are products of in vivo affinity maturation, a process far more sophisticated than any in vitro method. |
| Phage Display Format | Massive Library Screening | Allows for the interrogation of libraries exceeding 10^10 clones, ensuring comprehensive epitope coverage. |
| Direct Genotype-Phenotype Link | Rapid Hit Identification | The gene (in the phagemid) is physically linked to the protein (on the phage coat), enabling immediate sequencing. |
| Use of Human Donors | Minimal to Zero Immunogenicity | Bypasses the need for antibody humanization, saving months of development time and reducing risk. |
| Optimized Panning Strategies | Isolation of Rare Binders | We employ solid-phase, solution-phase, and cell-based panning to isolate antibodies against challenging targets. |
| Full V-Gene Repertoire | Exceptional Diversity | Our proprietary PCR amplification and cloning techniques capture the complete VH and VL repertoire from donors. |
Creative Biolabs offers a fully integrated, end-to-end service for Human Monoclonal Antibody Discovery. Our process is transparent, rapid, and tailored to your specific target.
As industry pioneers, we integrate the latest technological advancements to ensure the success of your Human Monoclonal Antibody Discovery project.
The quality of a human immunized antibody library is defined by its diversity. A bottleneck at the cloning stage can irrevocably damage the project. Our molecular biology team has optimized primer sets and ligation-independent cloning (LIC) protocols to ensure the unbiased and highly efficient capture of all V-gene families present in the donor's B-cell population. This preserves the natural diversity created by the immune system.
Finding a "needle in a haystack" requires the right magnet. Our biopanning strategies are not one-size-fits-all. We design a custom panning protocol based on your target's nature:
A successful discovery project concludes with a lead candidate. Creative Biolabs provides a seamless transition to the next phase. Our integrated services include:
Selecting the right CRO partner is the most critical decision in your antibody's journey. With Creative Biolabs, you partner with an expert team committed to scientific excellence.
| Our Commitment | Your Benefit |
| 20+ Years of Phage Display Expertise | An industry-leading, highly optimized platform with a proven track record of success. |
| Focus on Immune Libraries | Access to high-affinity, in vivo matured antibodies with superior developability characteristics. |
| Comprehensive Target Experience | Success in isolating antibodies against "difficult" targets, including GPCRs, ion channels, and low-immunogenicity proteins. |
| Customized Project Design | We are not a kit. We are scientists. Every project is designed by a PhD-level expert to meet your specific goals. |
| Speed and Efficiency | Our streamlined workflow delivers fully characterized lead candidates in a matter of weeks, not months. |
| End-to-End Solutions | A single, reliable partner from antigen design and Human Monoclonal Antibody Discovery all the way to IND-enabling studies. |
While our phage display immune antibody library platform is a powerful engine, we offer a comprehensive suite of discovery technologies to ensure we always use the right tool for the job. Our Monoclonal Antibody Generation from Various Immunized Antibody Libraries Services:
Your next breakthrough therapeutic is waiting to be discovered. Partner with the experts at Creative Biolabs and leverage our advanced Human Monoclonal Antibody Discovery platform. Contact our scientific team today to discuss your project. We will provide a detailed, customized proposal to accelerate your research from target to therapeutic.
Q: What is the main advantage of an immune antibody library over a naïve library?
A: An immune antibody library is constructed from donors who have already launched an immune response to the antigen. This means the antibodies within the library have undergone in vivo affinity maturation and somatic hypermutation. As a result, they typically have much higher affinity, greater specificity, and better in vivo characteristics from the outset, accelerating the discovery of therapeutic-grade candidates.
Q: How large are your phage display libraries?
A: Our human immunized antibody libraries typically achieve diversities in the range of 10^8 to 10^10 colony-forming units (cfu). This vast diversity is essential for comprehensive screening and ensuring the isolation of rare and potent binders against multiple epitopes.
Q: What input material do you need for the construction and screening of a human immune antibody library?
A: The ideal starting material is peripheral blood mononuclear cells (PBMCs) from donors with confirmed exposure to the antigen (e.g., convalescent patients or vaccinated individuals). We typically require sufficient B-cell numbers for high-diversity library construction. We can assist with donor sourcing and screening.
Q: How do you ensure the antibodies discovered are fully "human"?
A: Our process starts with human donors. We amplify the V-gene (variable region) repertoire directly from human B-cells. These V-genes are then cloned and expressed in frame with a human constant region (e.g., IgG1). The resulting antibody is fully human, not humanized, which dramatically reduces the risk of immunogenicity.
Q: What if my target is non-immunogenic or toxic in humans?
A: If a target is non-immunogenic or highly conserved (a "self-antigen"), it can be difficult to source donors for a human immunized antibody library. In this scenario, we would recommend our high-diversity human naïve library or one of our synthetic libraries, which bypass the need for an immune response.
All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.
